Health Care Providers Have Knowledge Gap On Biosimilars, Accelerated Approval
Executive Summary
FDA’s 2019 survey of 2,000 providers finds 31% do not know what biosimilars are and 30% of primary care physicians do not know what an accelerated approval drug is. Another survey of low- or non-internet users finds a toll-free number is the best way for them to find information about a drug’s risks.
You may also be interested in...
TV Drug Advertising Study Targets Those With Limited Or No Internet Use
US FDA will assess value of including 1-800 number and print ad in broadcast commercials; it is among 42 direct-to-consumer studies the agency has undertaken, 13 of which are in progress.
Pharma Companies Need To ‘Think A Little Bigger’ To Avoid Government Enforcement Actions
Industry executives note lessons learned from ‘fascinating’ approaches DOJ and states have taken in recent settlements, from restrictions on Novartis speaker programs to targeting McKinsey’s marketing advice. Chart includes details of 18 settlements since January 2020.
US FDA’s Rx Drug Promo Study Answers $798,000 Question
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.